Abstracts tagged "COVID-19"

Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 1938 • ACR Convergence 2022
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
Francesca Minoia¹, Federica Lucioni¹, Merav Heshin-Bekenstein², Sebastiaan Vastert³, Christoph Kessel⁴, Yosef Uziel⁵, Lovro Lamot⁶, Nicola Ruperto⁷, Marco Gattorno⁸, Claudia Bracaglia⁹ and Natasa Toplak¹⁰, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ³Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, ⁵Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁶University Hospital Center Zagreb, Zagreb, Croatia, ⁷IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ⁸Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰University Children's Hospital, University Medical Centre, Ljubljana, Slovenia
Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
Abstract Number: 2272 • ACR Convergence 2022
Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Yumeko Kawano¹, Naomi Patel², Xiaosong Wang¹, Claire Cook³, Kathleen Vanni¹, Emily Kowalski¹, Emily Banasiak¹, Grace Qian¹, Michael Diiorio¹, Tiffany Hsu¹, Michael Weinblatt⁴, Derrick Todd¹, Zachary Wallace³ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Advances in prevention, testing, and treatment of COVID-19 have contributed to less severe outcomes in the general population, but whether outcomes have improved for…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L03 • ACR Convergence 2021
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
Abstract Number: L04 • ACR Convergence 2021
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
Jean Liew¹, milena Gianfrancesco², Carly Harrison³, zara Izadi², Stephanie Rush², Lindsay Jacobsohn², Clairissa Ja², Saskia Lawson-Tovey⁴, Kimme Hyrich⁵, Laure Gossec⁶, Anja Strangfeld⁷, Loreto Carmona⁸, Martin Schaefer⁷, ELSA MATEUS⁹, Samar Al Emadi¹⁰, Claire Cook¹¹, Fatemah Abutiban¹², Dfiza Dey¹³, Emily Kowalski¹⁴, Marco Martinez-Martinez¹⁵, Naomi Patel¹¹, Evelyn Salido¹⁶, Jeffrey Sparks¹⁷, leanna Wise¹⁸, Suleman Bhana¹⁹, Wendy Costello²⁰, Rebecca Grainger²¹, Jonathan Hausmann²², Emily Sirotich²³, Paul Sufka²⁴, Zachary Wallace²⁵, Pedro Machado²⁶, Philip Robinson²⁷ and Jinoos Yazdany², ¹Boston University School of Medicine, Boston, MA, ²University of California San Francisco, San Francisco, CA, ³Lupus Chat, New York, NY, ⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, ⁷German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain, ⁹EULAR, Lisboa, Portugal, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Massachusetts General Hospital, Boston, MA, ¹²Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, ¹³Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁵Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, ¹⁶University of the Philippines Manila, Manila, Philippines, ¹⁷Brigham and Women's Hospital, Boston, MA, ¹⁸University of Southern California, Los Angeles, CA, ¹⁹Pfizer, Montvale, NJ, ²⁰Irish Children's Arthritis Network (iCAN), Bansha, Ireland, ²¹University of Otago, Wellington, New Zealand, ²²Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²³McMaster University, Hamilton, ON, Canada, ²⁴HealthPartners, Eagan, MN, ²⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, ²⁷University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
Abstract Number: L09 • ACR Convergence 2021
A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children
Matthew Clark¹, Danielle Rankin², Alisa Gotte¹, Alison Herndon¹, William McEachern¹, Andrew Smith³, Daniel Clark¹, Edward Hardison¹, Anna Patrick¹, Lauren Peetluk¹, Natasha Halasa¹, James Connelly¹ and Sophie Katz¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 0108 • ACR Convergence 2021
Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Akhil Sood¹, Vijaya Murthy¹ and Emilio Gonzalez², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch (utmb Health), Galveston, TX
Background/Purpose: The mRNA-based SARS-CoV-2 vaccine has shown efficacy in large vaccine trials. However, patients on immunosuppressive therapies including those with rheumatic disease (RD) were excluded.…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].